Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

The results of the current study, which focused on a number of individual components of clinical response, demonstrated that patients with ET who are refractory to or intolerant of hydroxyurea can achieve clinically meaningful and durable reductions in platelet and WBC counts and improvements in ET-related symptoms with ruxolitinib treatment.